http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-046758-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0202 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-107 |
| filingDate | 2004-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2005-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-046758-A1 |
| titleOfInvention | INHIBITORS OF THE NS3 / NS4A SERINA PROTEASA OF THE HEPATITIS C VIRUS |
| abstract | The present discloses compounds that have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the present discloses pharmaceutical compositions comprising such compounds as well as methods for using them to treat disorders associated with HCV protease. Claim 1: A compound, or enantiomers, stereoisomers, rotamers, tautomers, diastereomers or racemates of said compound, or a salt, solvate or ester acceptable for pharmaceutical use of said compound, said compound having the general structure shown in the formula ( 1), in which: R1 is H, OR8, NR9R10 or CHR9R10, where R8, R9 and R10 can be the same or different, each being independently selected from the group consisting of H, alkyl-, aryl-, heteroalkyl-, heteroaryl-, cycloalkyl-, cycloalkyl-, arylalkyl-, and heteroarylalkyl; E and J can be the same or different, each being independently selected from the group consisting of R, OR, NHR, NRR7, SR, halo and S (O2) R, or E and J can be connected directly to each other to form either a three to eight membered cycloalkyl, or a three to eight membered heterocyclyl moiety; Z is N (H), N (R) or O, with the proviso that when Z is O, G is present or absent and if G is present when Z is O then G is C (= O); G may be present or absent, and if G is present, G is C (= O) or S (O2), and when G is absent, Z is directly connected to Y; And it is selected from the group of formulas (2); R, R7 R2, R3, R4 and R5 may be the same or different, each being independently selected from the group consisting of H, alkyl-, alkenyl-, alkynyl-, cycloalkyl-, heteroalkyl-, heterocyclyl-, aryl-, heteroaryl -, (cycloalkyl) alkyl-, (heterocyclyl) alkyl-, aryl-alkyl- and heteroaryl-alkyl-, wherein each of said heteroalkyl, heteroaryl and heterocyclyl independently has from one to six oxygen, nitrogen, sulfur atoms, or phosphorus; wherein each of said alkyl, heteroalkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocyclyl moieties may be unsubstituted or optionally independently substituted with one or more moieties selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, aralkyl , cycloalkyl, heterocyclyl, halo, hydroxy, thio, alkoxy, aryloxy, alkylthio, arylthio, amino, amido, ester, acid, carboxylic, carbamate, urea, ketone, aldehyde, cyano, nitro, sulfonamido, sulfoxide, sulfone, sulfonyl urea, hydrazide and hydroxamate. |
| priorityDate | 2003-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.